천식 및 만성폐쇄성폐질환(COPD) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Asthma And COPD Market size is expected to reach USD 65.44 Billion in 2034 from USD 42.25 Billion (2025) growing at a CAGR of 4.98% during 2026-2034.

The Global Asthma And COPD Market is witnessing substantial growth driven by rising air pollution levels, increasing tobacco consumption, and growing prevalence of respiratory disorders. Urbanization and industrialization have contributed to deteriorating air quality, leading to higher diagnosis rates. Pharmaceutical companies are investing in innovative inhalers, biologics, and combination therapies to enhance disease management.

Major growth drivers include advancements in targeted biologic therapies, increased healthcare spending, and supportive government initiatives for respiratory health awareness. The introduction of smart inhalers with digital monitoring features is improving patient adherence and treatment outcomes. Growing clinical research and expansion of generic drug availability are further strengthening market competitiveness.

Looking forward, the market is poised for continued expansion with rising adoption of personalized treatment approaches and improved diagnostic capabilities. Emerging economies are expected to witness strong growth due to expanding healthcare infrastructure. Ongoing research in long-acting bronchodilators and anti-inflammatory agents will likely shape the future landscape and enhance long-term revenue potential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Diseases

• Asthma
• COPD

By Medication Class

• Combination Drugs
• Short Acting Beta Agonists (SABA)
• Long Acting Beta Agonists (LABA)
• Leukotriene Antagonists (LTA)
• Anticholinergics
• Others

COMPANIES PROFILED

• GlaxoSmithKline Plc, AstraZeneca Plc, HoffmannLa Roche Ltd, Vectura Group Plc, Organon, Abbott Laboratories, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA AND COPD MARKET: BY DISEASES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diseases
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA AND COPD MARKET: BY MEDICATION CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Medication Class
• 5.2. Combination Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Short Acting Beta Agonists (SABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Long Acting Beta Agonists (LABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Leukotriene Antagonists (LTA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anticholinergics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA AND COPD MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Diseases
  • 6.2.2 By Medication Class
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Diseases
  • 6.3.2 By Medication Class
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Diseases
  • 6.4.2 By Medication Class
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Diseases
  • 6.5.2 By Medication Class
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Diseases
  • 6.6.2 By Medication Class
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ASTHMA AND COPD INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 GlaxoSmithKline Plc
  • 8.2.2 AstraZeneca Plc
  • 8.2.3 Hoffmann-La Roche Ltd
  • 8.2.4 Vectura Group Plc
  • 8.2.5 Organon
  • 8.2.6 Abbott Laboratories
  • 8.2.7 Boehringer Ingelheim International GmbH
  • 8.2.8 Teva Pharmaceutical Industries Ltd
  • 8.2.9 Novartis AG
  • 8.2.10 Sanofi